ADT is either surgical (bilateral orchiectomy) or chemical (gonadotropin-releasing hormone (GnRH) agonists or oral anti-androgens) and has long been a standard treatment for metastatic prostate cancer and is also part of the treatment of prostate cancer patients with locally advanced or high-risk disease as neoadjuvant and adjuvant ADT in conjunction with radiotherapy [24–26]. This evidence concerns the gene GNRH1 and prostate carcinoma.